CIC
STRO icon

Chase Investment Counsel’s Sutro Biopharma STRO Stock Holding History

Chase Investment Counsel’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,770
Closed -$326K – 146
2024
Q1 		$326K Buy
+5,770
New +$255K 0.12% 117

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Chase Investment Counsel's STRO Position: Q2 2024 in Review

Chase Investment Counsel sold out of Sutro Biopharma (STRO) in Q2 2024, closing a stake of 5,770 shares — an estimated $326K sold.

Chase Investment Counsel first reported a position in STRO in Q1 2024 and held it in 1 quarter. The position peaked at $326K in Q1 2024. 119 funds tracked by Wall St. Rank hold STRO as of Q2 2024.

  • Chase Investment Counsel reported no remaining Sutro Biopharma position as of Q2 2024 after selling out during the quarter.
  • Chase Investment Counsel sold 5,770 Sutro Biopharma shares in Q2 2024, an estimated $326K.
  • Chase Investment Counsel first reported a position in Sutro Biopharma in Q1 2024 and held it in 1 quarter.
  • Chase Investment Counsel's Sutro Biopharma position peaked at $326K in Q1 2024.
  • 119 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2024.

Based on Chase Investment Counsel's 13F filing for Q2 2024, filed 2 Aug 2024.